The Formulary has been developed by the Medicines Optimisation Committee (MOC) of Midlands Partnership NHS Foundation Trust and through consultation with clinicians. Details of the MOC membership can be found on the Trusts Internet at http://sp.mpft.nhs.uk/. The Formulary represents a collaborative approach to medicines optimisation between the Trust and its key Primary Care Partners
The Aim of the Formulary is to advise clinicians on evidence based drug treatments (which are cost and clinically effective) and commonly encountered in clinical practice.
The Formulary is applicable to all doctors and all Non-Medical Prescribers (NMPs) whose individual Formularies will be agreed with the Advanced Nurse, Medicines Optimisation, the NMP and their Designated Medical Practitioner.
All drugs should be prescribed generically unless a particular preparation needs to be specified because of variations in bioavailability between different brands, these are identified in the Formulary. It is recognised that on occasion non-formulary items will be legitimately requested although in such circumstances pharmacists may seek a rationale from the prescribing clinicians. Licensed products should be used wherever possible.
It is anticipated that this Formulary will evolve through debate and suggestion and as new drugs become available. Requests for amendments to the formulary should be made by submitting the Application to Amend the Formulary Form which can be accessed from either the netFormulary or at the following web page: http://www.sssft.nhs.uk/services/pharmacy/information-for-professionals/formulary. Genuine ownership of the Formulary by clinicians in the Trust will help to refine it and enhance its relevance to everyday clinical practice.
A price banding system has been included; the aim of the banding is to give the prescribing clinician an idea of the cost. The costs have been calculated using the May 16 Drug Tariff prices with the exception of the Inclusion section which uses the December 17 Drug Tariff prices (the cost to primary care). Prices are for oral, immediate release preparations, 28 days supply at the highest BNF dose. Clinicians should note from this information that differences between formulations of the same drug can be significant as medicines come off Patent e.g. XL formulations, patches, orodispersible products
Each drug has been colour coded: green means any clinician can prescribe, amber means it is appropriate for all clinicians but must be initiated by a specialist and the patient stabilised before shared care is considered & red means specialist services only.
Essential Shared Care Agreements or Best Practice Guidelines have been agreed for deployment in certain areas, they can be found on netFormulary or the Trusts website at http://www.sssft.nhs.uk/services/pharmacy/information-for-professionals/essential-shared-care-agreements-escas.
The National Patient Safety Agency has published a Reduction of Self Harm and High Risk Drugs, which can be found on the Trusts website at: http://www.sssft.nhs.uk/services/pharmacy/information-for-professionals/high-risk-drugs-list.
The Royal College of General Practitioners and Secure Environments Pharmacists Group have published guidance on Safer Prescribing in Prison, which can be found at http://www.rcgp.org.uk/clinical-and-research/clinical-resources/~/media/106D28C849364D4CB2CB5A75A4E0849F.ashx.